Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934740 | 0.71 | NTRK1 (0.31) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL25822881 | 0.71 | NTRK1 (0.31) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL30060196 | 0.71 | CCR1 (0.44) | KDM4ENPC1RAB9ASMN1; SMN2NTRK1 | |
| SCHEMBL422300 | 0.71 | CCR1 (0.44) | KDM4ENPC1RAB9ASMN1; SMN2NTRK1 | |
| SCHEMBL4124057 | 0.71 | NTRK1 (0.31) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL857548 | 0.68 | CLK4 (0.33) | KDM4ESMN1; SMN2NTRK1LTKTYRO3 | |
| SCHEMBL24037449 | 0.67 | CCR4 (0.33) | NPC1RAB9ANTRK1LTKTYRO3 | |
| SCHEMBL9934727 | 0.67 | ELANE (0.33) | NTRK1NTRK2CLK4 | |
| SCHEMBL16685781 | 0.67 | CYP2D6 (0.39) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL21388633 | 0.67 | LMNA (0.37) | NTRK1LTKTYRO3NTRK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4298092-A1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| CN-116829550-A | Pyrimidine-2-ylsulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11713291-B2 | Compound for organic electronic device, organic electronic device using same, and electronic apparatus thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2023-08-01 | — | — | US | disclosed |
| US-11713291-B2 | Compound for organic electronic device, organic electronic device using same, and electronic apparatus thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2023-08-01 | — | — | US | disclosed |
| US-20230157160-A1 | COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE | DUK SAN NEOLUX CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230157160-A1 | COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE | DUK SAN NEOLUX CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-11552253-B2 | Compound for organic electric device, organic electric device using same, and electronic device | DUK SAN NEOLUX CO., LTD. (KR) | 2023-01-10 | — | — | US | disclosed |
| US-8999991-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140288088-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-09-25 | — | — | US | disclosed |
| EP-2771004-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013062900-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-6602864-B1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-05 | — | — | US | disclosed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288088-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | KDM4E 2161/4885NPC1 477/4885RAB9A 1764/4885 |
| US-11713291-B2 | Compound for organic electronic device, organic electronic device using same, and electronic apparatus thereof | PIEZO1, ORAI2, EXOC1 | KDM4E 1772/4885NPC1 3642/4885RAB9A 978/4885 |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | GPR17, GPR27, GPR119 | KDM4E 3786/4885NPC1 424/4885RAB9A 3289/4885 |
| US-11552253-B2 | Compound for organic electric device, organic electric device using same, and electronic device | OR10J3, OR51E2, ORAI2 | KDM4E 672/4885NPC1 4575/4885RAB9A 3770/4885 |
| US-20230157160-A1 | COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE | OR10J3, OR51E2, ORAI2 | KDM4E 671/4885NPC1 4493/4885RAB9A 3674/4885 |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | KDM4E 4144/4885NPC1 3097/4885RAB9A 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.